Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.50 |
| ▸ | HTR2A | P28223 | 10/20 | 0.50 |
| ▸ | HTR2B | P41595 | 10/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895785 | 0.90 | HTR2C (0.55) | HTR2CHTR2AHTR2B | |
| Carbamic Acid SCHEMBL1895506 | 0.86 | HTR2C (0.39) | HTR2CHTR2AHTR2B | |
| Carbamic Acid SCHEMBL1895202 | 0.78 | HTR2C (0.43) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Carbamic Acid SCHEMBL1895153 | 0.74 | HTR2C (0.39) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Carbamic Acid SCHEMBL1896139 | 0.74 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| Carbamic Acid SCHEMBL1893874 | 0.72 | HTR2C (0.40) | HTR2CHTR2B | |
| Carbamic Acid SCHEMBL1892618 | 0.70 | HTR2C (0.64) | HTR2CHTR2AHTR2B | |
| Carbamic Acid SCHEMBL1894490 | 0.70 | HTR2C (0.82) | HTR2CHTR2AHTR2B | |
| SCHEMBL13756908 | 0.67 | HTR2A (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL13756907 | 0.67 | HTR2A (1.00) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096520-B2 | Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators | ABT HOLDING COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ABT HOLDING COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716324-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | ATHERSYS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8232311-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2011-07-14 | — | — | US | disclosed |
| US-7935830-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1841738-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007081299-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | HTR2C 6/4885HTR2A 10/4885HTR2B 18/4885 |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | HTR2C 6/4885HTR2A 10/4885HTR2B 18/4885 |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | HTR5A, HTR3E, HTR1E | HTR2C 6/4885HTR2A 10/4885HTR2B 18/4885 |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | HTR2C 6/4885HTR2A 10/4885HTR2B 18/4885 |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | HTR2C 6/4885HTR2A 10/4885HTR2B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.